1251528-23-0
Chemical Structure
ALK4290
Synonym(s): AKST4290; BI144807
- CAS No.: 1251528-23-0
- Formula:C27H34ClN5O3
- Molecular Weight:512.04
IUPAC Name: (R)-2-(1-(1-(4-chloro-3-methylbenzyl)piperidin-4-yl)-5-oxopyrrolidine-2-carboxamido)-N,N,6-trimethylisonicotinamide
InChIKey: DWKNOLCXIFYNFV-HSZRJFAPSA-N
SMILES: O=C(C1=CC(NC([C@@H](CC2)N(C3CCN(CC4=CC=C(Cl)C(C)=C4)CC3)C2=O)=O)=NC(C)=C1)N(C)C
Biological Activity: ALK4290 (AKST4290) is a potent, orally active and selective CCR3 inhibitor with a Ki of 3.2 nM. ALK4290 blocks CCR3-mediated signaling, abrogates macrophage supernatant-driven mesothelial-to-mesenchymal transition, and decreases p38 phosphorylation. ALK4290 inhibits CCL26-CCR3 axis-driven GPX2-mediated B-cell activation, and targets B cells to inhibit activation by GPX2-overexpressing tumor cells. ALK4290 can be used for the research of hepatocellular carcinome and Parkinson’s disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ALK4290 | 99.79% | ALK4290 (AKST4290) is a potent, orally active and selective CCR3 inhibitor with a Ki of 3.2 nM. ALK4290 blocks CCR3-mediated signaling, abrogates macrophage supernatant-driven mesothelial-to-mesenchymal transition, and decreases p38 phosphorylation. ALK4290 inhibits CCL26-CCR3 axis-driven GPX2-mediated B-cell activation, and targets B cells to inhibit activation by GPX2-overexpressing tumor cells. ALK4290 can be used for the research of hepatocellular carcinome and Parkinson’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zhao X, et al. Peritoneal MSCs-derived exosomes suppress CCL24 synthesis through miR-320d delivery contributing to the improvement of peritoneal dialysis-associated fibrosis. Sci Rep. 2026;16(1):11998. Published 2026 Mar 4. [Content Brief]
- [2]. Lin L, et al. GPX2+ tumor cells recruit LGALS1+ B cells via CCL26-CCR3 axis to promote immunosuppression and tumor progression in hepatocellular carcinoma. Front Immunol. 2026;17:1709855. Published 2026 Mar 20. [Content Brief]
- [3]. NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.
- [4]. Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic.
Keywords
